Cognetivity Neurosciences Ltd. (CGNSF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cognetivity Neurosciences Ltd. (CGNSF) with AI Score 58/100 (Hold). Cognetivity Neurosciences Ltd. is a technology company focused on developing cognitive assessment platforms for early dementia diagnosis. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Cognetivity Neurosciences Ltd. (CGNSF) Healthcare & Pipeline Overview
Cognetivity Neurosciences Ltd. develops and commercializes cognitive assessment technology, including a platform for early dementia diagnosis and the OptiMind wellness app. Operating within the health information services sector, the company targets medical, commercial, and consumer markets with its innovative cognitive testing solutions.
Investment Thesis
Cognetivity Neurosciences presents a compelling investment thesis centered on its innovative cognitive assessment technology. The company's focus on early dementia diagnosis addresses a significant and growing market need, driven by an aging global population. Key value drivers include the adoption of Cognetivity's platform by healthcare providers, pharmaceutical companies, and research institutions. Growth catalysts include expanding regulatory approvals and partnerships. However, the company's limited financial resources and reliance on securing additional funding pose potential risks. Investors should monitor the company's progress in securing commercial contracts and achieving regulatory milestones to assess the viability of its long-term growth strategy. The company's beta of 0.87 suggests lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
Key Highlights
- Cognetivity Neurosciences Ltd. operates in the health information services sector, focusing on cognitive assessment technology.
- The company's primary product is an integrated cognitive assessment platform designed for early dementia diagnosis.
- Cognetivity also offers OptiMind, a wellness app aimed at promoting cognitive health.
- The company's market capitalization is $0.00B, indicating its current size and stage of development.
- Cognetivity's free cash flow is $-0.00B, reflecting its investment phase and need for external funding.
Competitors & Peers
Strengths
- Innovative cognitive assessment technology
- Integrated platform for diverse applications
- Focus on early dementia diagnosis
- OptiMind wellness app offering
Weaknesses
- Limited financial resources
- Dependence on external funding
- Limited market presence
- Unknown disclosure status
Catalysts
- Upcoming: Potential regulatory approvals for the cognitive assessment platform.
- Upcoming: Strategic partnerships with pharmaceutical companies for clinical trials.
- Ongoing: Increasing adoption of telehealth platforms driving demand for remote cognitive assessments.
Risks
- Potential: Limited financial resources and dependence on external funding.
- Potential: Competition from established medical device companies.
- Potential: Regulatory hurdles and reimbursement challenges.
- Ongoing: Technological obsolescence in the rapidly evolving healthcare technology sector.
Growth Opportunities
- Expansion into New Geographic Markets: Cognetivity has the opportunity to expand its market presence beyond its current operational areas. Targeting regions with aging populations and increasing healthcare spending, such as Europe and Asia, could significantly boost revenue. This expansion could involve strategic partnerships with local healthcare providers and distributors to navigate regulatory requirements and market access challenges. The global market for dementia care is projected to reach $1 trillion by 2030, presenting a substantial opportunity for Cognetivity to capture market share.
- Strategic Partnerships with Pharmaceutical Companies: Collaborating with pharmaceutical companies to integrate Cognetivity's platform into clinical trials and drug development programs represents a significant growth opportunity. By providing cognitive assessment tools for monitoring treatment efficacy and identifying potential drug candidates, Cognetivity can generate recurring revenue streams and enhance its market credibility. The pharmaceutical industry invests billions annually in Alzheimer's disease research, creating a strong demand for innovative cognitive assessment solutions.
- Integration with Telehealth Platforms: As telehealth adoption continues to rise, integrating Cognetivity's platform with telehealth providers can expand its reach and accessibility. This integration would allow remote cognitive assessments, improving patient convenience and reducing healthcare costs. The telehealth market is projected to reach $175 billion by 2026, offering a substantial opportunity for Cognetivity to capitalize on the growing demand for remote healthcare services.
- Development of New Cognitive Assessment Modules: Expanding the functionality of Cognetivity's platform by developing new cognitive assessment modules targeting specific cognitive domains or patient populations can enhance its value proposition. This could involve creating modules for assessing cognitive function in children, individuals with traumatic brain injuries, or patients with mental health disorders. By diversifying its product offerings, Cognetivity can attract a broader range of customers and generate additional revenue streams.
- Securing Regulatory Approvals and Reimbursement: Obtaining regulatory approvals from agencies such as the FDA and securing reimbursement from healthcare payers are critical for driving adoption of Cognetivity's platform. These approvals would validate the clinical efficacy of the platform and facilitate its integration into standard clinical practice. The process of securing regulatory approvals and reimbursement can be lengthy and costly, but it is essential for establishing Cognetivity's credibility and market acceptance.
Opportunities
- Expansion into new geographic markets
- Strategic partnerships with pharmaceutical companies
- Integration with telehealth platforms
- Development of new cognitive assessment modules
Threats
- Competition from established medical device companies
- Regulatory hurdles and reimbursement challenges
- Technological obsolescence
- Economic downturn affecting healthcare spending
Competitive Advantages
- Proprietary cognitive assessment technology
- Integrated platform for diverse applications
- Focus on early dementia diagnosis
About CGNSF
Cognetivity Neurosciences Ltd., established in 2015 and headquartered in Vancouver, Canada, is a technology company specializing in the development of cognitive assessment platforms. Originally incorporated as Utor Capital Corp., the company rebranded in December 2017 to reflect its focus on neuroscience and cognitive health. Cognetivity's core product is an integrated cognitive assessment platform designed for use across medical, commercial, and consumer environments. This platform aims to facilitate the early diagnosis of dementia by providing a rapid and reliable cognitive testing solution. In addition to its diagnostic platform, Cognetivity offers OptiMind, a wellness app designed to promote cognitive health and well-being. The company's solutions are geared towards improving patient outcomes and reducing the burden of cognitive impairment on healthcare systems and individuals. Cognetivity's technology seeks to provide accessible and scalable cognitive assessment tools, addressing the growing need for early detection and management of cognitive decline.
What They Do
- Develops an integrated cognitive assessment platform.
- Offers a cognitive testing platform for medical use.
- Provides cognitive testing solutions for commercial environments.
- Creates cognitive testing tools for consumer applications.
- Aims to enable early diagnosis of dementia.
- Offers OptiMind, a wellness app for cognitive health.
Business Model
- Develops and sells cognitive assessment platforms.
- Generates revenue through licensing agreements with healthcare providers.
- Offers subscriptions to the OptiMind wellness app.
Industry Context
Cognetivity Neurosciences operates within the health information services sector, which is experiencing rapid growth driven by technological advancements and increasing demand for digital health solutions. The market for cognitive assessment tools is expanding due to the rising prevalence of dementia and the need for early diagnosis and intervention. The competitive landscape includes established medical device companies, as well as emerging technology firms focused on AI-powered diagnostics. Cognetivity aims to differentiate itself through its integrated platform and focus on accessibility and scalability.
Key Customers
- Medical professionals and healthcare providers
- Commercial organizations seeking cognitive assessment tools
- Consumers interested in cognitive health and wellness
Financials
Chart & Info
Cognetivity Neurosciences Ltd. (CGNSF) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Oct 8, 2019
-
Stocks That Hit 52-Week Lows Of Monday
· Oct 7, 2019
-
Stocks That Hit 52-Week Lows On Monday
· Sep 30, 2019
-
Stocks That Hit 52-Week Lows On Thursday
· Aug 15, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CGNSF.
Price Targets
Wall Street price target analysis for CGNSF.
MoonshotScore
What does this score mean?
The MoonshotScore rates CGNSF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Classification
Industry Health Information ServicesCompetitors & Peers
CGNSF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Cognetivity Neurosciences Ltd. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity can be sporadic. This tier is distinct from exchanges like NYSE or NASDAQ, which have stringent listing requirements and offer greater transparency and regulatory oversight. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited liquidity and information.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity due to low trading volume
- Lack of regulatory oversight compared to major exchanges
- Potential for information asymmetry due to limited disclosure
- Higher price volatility
- Risk of delisting or trading suspension
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and technology.
- Check for any legal or regulatory issues.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Company is incorporated and headquartered in Canada.
- Company has a clear business model focused on cognitive assessment.
- Company has a functional website and investor relations page.
Cognetivity Neurosciences Ltd. Stock: Key Questions Answered
What does Cognetivity Neurosciences Ltd. do?
Cognetivity Neurosciences Ltd. is a technology company focused on developing and commercializing cognitive assessment platforms. Its primary product is an integrated cognitive assessment platform designed for early diagnosis of dementia, targeting medical, commercial, and consumer markets. The company also offers OptiMind, a wellness app focused on cognitive health. By providing accessible and scalable cognitive assessment tools, Cognetivity aims to improve patient outcomes and reduce the burden of cognitive impairment on healthcare systems.
What do analysts say about CGNSF stock?
As of March 16, 2026, formal analyst coverage of Cognetivity Neurosciences Ltd. (CGNSF) appears limited, likely due to its OTC listing and smaller market capitalization. Investors should conduct their own thorough due diligence, focusing on the company's financial health, market traction, and competitive landscape. Key valuation metrics to consider include revenue growth, cash burn rate, and potential for future profitability. Given the speculative nature of early-stage healthcare technology companies, a cautious approach is warranted.
What are the main risks for CGNSF?
Cognetivity Neurosciences faces several key risks, including limited financial resources and dependence on external funding. The company operates in a competitive landscape with established medical device companies and emerging technology firms. Regulatory hurdles and reimbursement challenges could hinder the adoption of its cognitive assessment platform. Additionally, the company faces the risk of technological obsolescence in the rapidly evolving healthcare technology sector. Investors should carefully assess these risks before investing in CGNSF.
What are the key factors to evaluate for CGNSF?
Cognetivity Neurosciences Ltd. (CGNSF) currently holds an AI score of 58/100, indicating moderate score. Key strength: Innovative cognitive assessment technology. Primary risk to monitor: Potential: Limited financial resources and dependence on external funding.. This is not financial advice.
How frequently does CGNSF data refresh on this page?
CGNSF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CGNSF's recent stock price performance?
Recent price movement in Cognetivity Neurosciences Ltd. (CGNSF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative cognitive assessment technology. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CGNSF overvalued or undervalued right now?
Determining whether Cognetivity Neurosciences Ltd. (CGNSF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CGNSF?
Before investing in Cognetivity Neurosciences Ltd. (CGNSF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC data may have limited reliability.
- Financial data is based on limited information.